Oruka Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Oruka Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $142.17. The average 1-year stock price forecast is 64.11% higher than the current stock price, while the lowest is $100 (+15.43%) and the highest is $200 (+130.87%).

Price Target: $142.17 (+64.11%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$100	$142.17	$141.5	$200
Change	+15.43%	+64.11%	+63.34%	+130.87%

Analyst Ratings

The average analyst rating for Oruka Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	11	11	11	11	11
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $120	Buy	Reiterates	$120	+38.52%	Jun 23, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $180	Buy	Maintains	$180	+107.78%	Jun 2, 2026
Michael Yee UBS	UBS	Buy Reiterates $100	Buy	Reiterates	$100	+15.43%	Jun 2, 2026
David Risinger Leerink Partners	Leerink Partners	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 2, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $125	Buy	Maintains	$125	+44.29%	May 23, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-2.04

from -1.85

EPS Next Year

-2.46

from -2.04

Fiscal Year	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-
Operating Income	-95.26M	-122.05M	-161.79M
Net Income	-91.34M	-105.43M	-143.19M
EPS	-	-1.85	-2.04
Free Cash Flow	-	-55.83M	-123.00M
No. Analysts	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.04
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-